Six-year (yr) follow-up of patients (pts) with imatinib-resistant or -intolerant chronic-phase chronic myeloid leukemia (CML-CP) receiving dasatinib.

被引：0

作者：

Shah, Neil P.

Kantarjian, Hagop

Kim, Dong-Wook

Hochhaus, Andreas

Saglio, Giuseppe

Guilhot, Francois

Schiffer, Charles Alan

Steegmann, Juan Luis

Mohamed, Hesham

Dejardin, David

Healey, Diane I.

Cortes, Jorge E.

机构：

[1] Univ Calif San Francisco, San Francisco, CA 94143 USA

[2] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[3] Catholic Univ Korea, Seoul, South Korea

[4] Univ Klinikum Jena, Jena, Germany

[5] Univ Turin, Orbassano, Italy

[6] Ctr Hosp Univ Poitiers, Poitiers, France

[7] Wayne State Univ, Detroit, MI USA

[8] Hosp Univ Princesa, Madrid, Spain

[9] Bristol Myers Squibb Co, Plainsboro, NJ USA

[10] Bristol Myers Squibb Co, Braine Lalleud, Belgium

[11] Bristol Myers Squibb Co, Wallingford, CT 06492 USA

来源：

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

6506

引用

页数：1